index

Note: page numbers in *italics* refer to figures; those in **bold** refer to tables and boxes

| acantholysis | 101 |
| acinic cheilitis | 68–9 |
| age | further disease risk | 150 |
| oral carcinogenesis | 43, 44 |
| alcohol counselling | 110–11 |
| alcoholic exposure | 3 |
| aetiology of oral cancer | 38, 39, 42 |
| disease recurrence | 111 |
| erythroplakia | 59 |
| further disease risk | 145, 150 |
| harmful | 173 |
| incidence of oral cancer | 7 |
| malignant transformation risk | 165 |
| malnutrition | 174 |
| multiple lesion disease | 71, 72 |
| oral cancer prevention | 9 |
| prevention of oral precancer | 172–3 |
| recurrent disease risk | 145, 150 |
| risk modification | 110–11 |
| risk of oral cancer | 38, 39, 42, 45 |
| soluble carcinogens | 29 |
| tobacco synergistic effects | 110 |
| alveolar mucosa | 16 |
| erythroplakia | 16 |
| laser surgery | 128–9 |
| alveolar ridges | 16 |
| amalgam restorations, lichenoid lesions | 194, 195, 196 |
| angiogenesis | 35, 179 |
| antifungal treatment | 200 |
| apoptosis | epithelial cells | 23 |
| evasion by cancer cells | 34–5 |
| basal cells | 17–18 |
| liquefaction degeneration | 204 |
| BcL-2 | 35 |
| betel-chewing | incidence of oral cancer | 7 |
| location of oral cancer | 29 |
| oral submucous fibrosis | 67 |
| prevention of oral cancer | 9 |
| bevacizumab | 179 |
| bioinformatics | 181 |
| biomarkers | 178–9 |
| biopsy | brush | 88–9, 90 |
| follow-up examination | 135 |
| field mapping | 82 |
| fixation of samples | 94–5 |
| incisional | 94, 175 |
| lichenoid lesions | 196 |
| mucosal punch | 95 |
| techniques | 94–6 |
| bleomycin | 112 |
| buccal mucosa | 19, 20 |
| erythroplakia | 118 |
| hyperkeratosis | 19, 20 |
| laser surgery | 117–21 |
| cadherins | 19 |
| cancer syndromes, inherited | 43 |
| candidosis | acute pseudomembranous | 58, 59 |
| chronic hyperplastic | 69–70 |
| case history | 199–201 |
| erythroplakia | 59 |
| carcinoembryonic antigen | 179 |
| carcinogenesis see oral carcinogenesis |
| carcinoma in situ | 99, 100, 100, 101 |
| differentiated | 101 |
| carotenoids | 112 |
| case histories | 187–206 |
| chronic hyperplastic candidosis | 199–201 |
| hyperkeratosis | 201–3 |
| immunosuppression | 198–9 |
| lichen planus malignant transformation | 203–5 |
| lichenoid lesions | 194–5 |
| dysplastic | 196–8 |
| multiple | 195–6 |
| multiple lesion disease | 189–91 |
| repeated laser treatment | 191–2 |
case histories (Continued)
proliferative verrucous leukoplakia 192–4
unexpected malignancy 187–9
cell cycle 18, 23–5
analysis 24–5
control loss 171–2
cellular adhesion molecules 19
cervical intra-epithelial neoplasia (CIN) 97
cervical lymph nodes
metastases 9
squamous cell carcinoma tumour spread 2, 3
cetuximab 179
chemoprevention, targeted 178–9
chemoradiotherapy
HPV-positive disease 9
post-surgical 134, 208
circumvallate papillae 14, 22, 23
Civatte bodies 204
clinical appearance of oral precancer 49–73
high-risk 61–3
multiple lesion disease 71–3
precancerous conditions 63–70
precancerous lesions 51–3, 54, 55–63
syphilis 70–1
terminology 49–51
clinical examination techniques 77–80, 81, 82–4
early diagnosis of malignancy 175
clinical outcome 139–55
definitions 142–5
laser surgery 146, 147
Newcastle 10-year follow-up study 147–9
Newcastle patient cohort studies 145–9
patient cohort studies 141–2
patient follow-up 149–50
study 147–9
prediction 150–1, 152–3, 153–4, 211
studies 139–41
clinical resolution 11
definition 142–3
collagen 18
counselling, alcohol use 110–11
cryotherapy 114
cyclin A labelling 151, 152, 153, 154
cyclin B1 labelling 151, 152, 153, 154
cyclo-oxygenase (COX) inhibitors 112
cyclo-oxygenase 2 (COX-2) 179
cyto brushes 88–9
cytokeratins 18
cytokines 19
dental care 211
oral cancer screening 77
routine 4
dental hygiene 39, 43
desmosomes 17
diagnosis
early 174–5
WHO classification 98
diagnostic methods 76–91
aids/adjuncts 83–7
brush biopsy 88–9, 90
clinical examination techniques 77–80, 81, 82–4, 175
exfoliate cytology 88–9, 90
histopathological examination 76
investigations 82
light-based detection systems 85–8
liquid-based cytology 89, 90
oral cancer 208
oral examination 76
in practice 91
recording 81
screening 76–7
vital tissue staining 84–5
diet
aetiology of oral cancer 38, 39, 42
multiple lesion disease 72
prevention of oral precancer 174
risk factor modification 111
risk of oral cancer 38, 39, 42
discoid lupus erythematosus 68, 69
disease-free state 142–3
DNA mutation, genetic predisposition 3
dyskeratosis congenita 70–1
dysplasia
clinical observation 111
cytological features 96
definition 10–11, 94
exfoliate cytology 96
floor of mouth 126, 127
grading 97, 99–100, 101, 102–3, 104
binary system 103, 104
HIV infection 63
keratinising 103
laboratory team 97
lichenoid 66
malignant transformation rate 160
mapping 82–3
multiple lesion disease 72–3
severity 165
VELscope® examination 87
elderly people  168
prognosis  43, 44
endothelial growth factor receptor (EGFR)  178–9
epidemiology of precancer state  6–7
epithelial cells
anatomical site distinction  27–8
apoptosis  23
cyclin A labelling  151, 152, 153, 154
cyclin B1 labelling  151, 152, 153, 154
differentiation  19, 23
dysplasia  4
definition  10–11
flash labelling indices  26
genetic predisposition to DNA mutations  3
instability  2
Ki67 labelling  151, 152, 153
kinetics  23–5
proliferation  19, 23, 25–8
activity variation  27–8, 171–2
dysregulation  150–1
labelling indices  27–8, 29, 151, 152, 153–4
squamous cell carcinoma  33–4
in vitro labelling technique  27–8
epithelium
atrophic  67
progenitor compartment  23
Epstein–Barr virus (EBV), hairy leukoplakia  43
erythroleukoplakia  10, 208
alveolar mucosa  16
buccal mucosa  118
clinical presentation  60–1
floor of mouth  127
laser excision  187, 188
erythroplakia  208
clinical presentation  59–60
definition  10
differential diagnosis  60
laser surgery of lateral tongue  124
malignant transformation  59–60
prevalence  8, 59
exfoliative cytology  88–9, 90, 96
experiential knowledge  183
extracellular matrix (ECM) remodelling  19
Fanconi’s anaemia  43
faucial pillars  16
clinical examination  78
laser surgery  127–8
oral submucous fibrosis  66
field change cancerisation  2, 71
definition  11
lichen planus  66
filiform papillae  22–3
floor of mouth  15
dysplasia  126, 127
erythroleukoplakia  127
laser surgery  126, 127
leukoplakia  16, 127, 175
mucosa  20–1
squamous cell carcinoma  14, 166
flow cytometry  24–5
fluconazole  200
foliate papillae  22, 23
follow-up
lichen planus protocols  205
long-term  210
management of oral precancer  134–5
Newcastle 10-year study  147–9, 164, 165
Fordyce’s spots  21
fungiform papillae  22, 23
further disease  175
definition  11, 145
gene therapy techniques  177
genetic factors, oral carcinogenesis  33, 34, 36, 36–7, 43, 45
genomic research  180
gingiva  21
clinical examination  79, 80, 81
laser surgery  128–9
masticatory mucosa  21
proliferative verrucous leukoplakia  57–8
glossectomy, partial by laser  121, 123, 124
growth factors  19
hairy leukoplakia  43
hard palate  15
clinical examination  79, 80
junction with soft palate  14
laser surgery  128–9
masticatory mucosa  21
head and neck, adjuvant radiotherapy  9
herpes simplex virus (HSV), attenuated  178
HIV infection  63
hairy leukoplakia  43
human body fluid proteome (HBFP) analysis  181
human papilloma virus (HPV) 4, 39, 43
  cervical intra-epithelial neoplasia 97
  prevention of oral precancer 173
  risk factor modification 111
  treatment 9
  vaccination programme 173
hyperkeratosis
  case history 201–3
  frictional 78
  lichen planus 66
  tobacco-associated 201–3
immunodeficiency 39, 43, 63
  risk factor modification 111
  risk of oral cancer 45
immunohistochemistry techniques 181
immunosuppression 63
  case history 198–9
  risk factor modification 111
  squamous cell carcinoma 198–9
immunotherapy 178
infections 4, 39, 43
  risk of oral cancer 45
  see also named conditions and organisms
integrins 19
interleukins 179
Kaplan–Meier survival analysis 149, 150, 153, 154, 164, 165
keratinocytes 17, 18, 23
  squamous cell carcinoma 33
  stem cells 25–6
Ki67 labelling 151, 152, 153
labial mucosa 19
lamina propria 18–19, 20
  oral submucous fibrosis 67
Langerhans’ cells 18
laser capture microdissection 181
laser surgery 114–33
  ablation 129
  alveolar mucosa 128–9
  anaesthesia 116, 116–17
  buccal mucosa 117–21
  chronic hyperplastic candidosis 200, 201
  clinical outcome 146, 147
  clinical resolution 142–3
  combined treatment modalities 134
  complications 130–3
  cytological artefacts 133
  erythroleukoplakia 187, 188
  excision 119–20, 129
  faucial pillar 127–8
  floor of mouth 126, 127
gingiva 128–9
haemorrhage 131–2
hard palate 128–9
interventional 114–33
  studies 146
irritation 132
lichenoid lesions 196, 197–8
multifocal leukoplakia 130
multiple lesion disease 130, 163
Newcastle 10-year follow-up study 164, 165
oral cancer prevention 163
patient impact 183
patient toleration 131
persistent disease 143, 144
postoperative management 120–1
proliferative verrucous leukoplakia 193
soft palate 127–8
squamous cell carcinoma 199, 204
  techniques 115–29
thermal damage 133
tongue
  dorum 122, 125
  lateral 121, 123, 124
  tethering 132
  ventral 123–4, 125
unexpected malignancy 167
leukoplakia 4, 5, 175, 208
  aetiology 43–4
  chronic hyperplastic candidosis 69, 70, 199–200
  clinical examination 79, 80
  techniques 78
  clinical presentation 51–3, 54, 55–8, 59
  definition 10, 51
  differential diagnosis 58, 59
  distinct lesions 55
  feint 81
  floor of mouth 16, 127, 175
  forms 53, 54
  hairy 43
  homogeneous 53, 54, 55
  immunocompromised patients 63
  incidence 51–2, 53
  laser ablation 129
  laser excision 121, 122
  malignant transformation 8, 62, 157, 159
  mixed 55, 56
  multifocal 6, 145, 188–91
  laser surgery 130
  multiple lesion disease 72
  new lesion development 56
  non-homogeneous 55
overlying submandibular duct 166, 175
persistent 143, 144
prevalence 7–8, 51, 53
recurrence risk 56
site 52
speckled 60–1
squamous cell carcinoma
development 157, 159–60
on tongue 157
syphilitic 70
tobacco exposure 52–3
tongue 15, 157
variations 53, 54
 verrucous 56, 145
widespread disease 55–6
see also proliferative verrucous
leukoplakia (PVL)
lichen planus 64, 65, 66
diagnosis 66
follow-up protocols 205
malignant transformation 64, 66
case history 203–5
squamous cell carcinoma 204–5
lichen lesions 64, 65, 66
amalgam restorations 194, 195, 196
case history 194–5
dysplastic 195–6
multiple 195–6
diagnosis 194
dysplastic 196–8
excision 194
follow-up protocols 205
incisional biopsy 196
laser surgery 196, 197–8
multiple 195–6
lifestyle, prevention of oral
precancer 174
light-based detection systems,
diagnostic 85–8
linea alba 19, 20
lingual nerve 15
lingual tonsils 23
lip
cancer 29
oral submucous fibrosis 66
vermillion border 19
liquid-based cytology 89, 90
Ljubljana classification 103, 104
lymphocyte exocytosis 204
malignant disease
clinical service 210, 211
eye early diagnosis 174–5
potential 208
unexpected 167–8, 187–9
malignant transformation 157–69
active surveillance 165
chronic hyperplastic candidosis 70
definition 11
detection 9
dysplasia 160
erythroplakia 59–60
high-risk 61, 62, 62–3, 165
leukoplakia 8, 62, 157, 159
lichen planus 64, 66
case history 203–5
low-risk patients 165
multiple lesion disease 73
Newcastle 10-year follow-up
study 164, 165
oral cancer development
distinction 161–3
oral submucous fibrosis 67
predictive factors 161, 162
prevention 209
process 34
prognosis 168
proliferative verrucous
leukoplakia 58
rates 157, 159–61
risk of progression to squamous cell
carcinoma 158–61
stratified squamous epithelium 3
unexpected 167–8
management of oral precancer 108–36,
208–9
biomarkers 178–9
centralisation of clinics 172–3
effectiveness of modalities 135
follow-up 210
future research directions 179–83
future strategies 177–8
gene therapy techniques 177
goals 108
immunotherapy 178
individualised treatments 178–9
interventional strategies 136,
175–8
medical interventions 112–13
multiple lesion disease 176–7
novel therapeutic/preventive
strategies 181–2
observation 111–12
cohort study 146–7
patient follow-up/
surveillance 134–5
randomised controlled trials 182
risk factor modification 109–11
surgical excision 108
management of oral precancer
(Continued)
surgical treatment 113–23, 124–5, 126–33
targeted chemoprevention 178–9
treatment modalities 109
viral vectors 177–8
see also laser surgery
mass spectrometry 181
melanocytes 18
Merkel cells 18
metastases
oral cancer 33
squamous cell carcinoma 166, 189
microarray technology 180
mitochondrial DNA (mtDNA) 180
mitosis 23
molecular biology 171–2
morphomics 181
mucocutaneous junction 14
multifocal precancer disease 176–7
multiple lesion disease 71–3
case history 189–91
repeated laser treatment 191–2
definition 11
diagnostic problem 82
laser surgery 130, 163
malignant transformation 73
management 176–7
prognosis 168
narrow emission tissue
fluorescence 86–7
neck dissection 9
new-site recurrence 145, 175
Newcastle 10-year follow-up study
clinical outcomes 147–9
malignant transformation 164, 165
non-steroidal anti-inflammatory drugs
(NSAIDs) 179
nutrition
aetiology of oral cancer 38, 39, 42
multiple lesion disease 72
prevention
oral cancer 9
oral precancer 174
risk of oral cancer 3–4, 38, 39, 42
observational study 146–7
oncogenes 36
OncoVEX viral vector 178
ONYX-015 viral vector 177–8
oral cancer 208
anatomical site predilection 29
apoptosis evasion 34–5
definition 10
development 162–3
diagnostic techniques 208
genetic instability 34
incidence 3, 7, 33, 34
worldwide 173
individuals at high risk 4–5
initiation 33
lip 29
metastasis 33
molecular markers 37, 38
mortality 2, 208
prevalence 7, 34
prevention 5, 8–9
laser surgery 163
primary prevention 8–9
progression 33
promotion 33
recurrence prevention 9
risk factors 3–4
risk of development 2
secondary prevention 9
survival rate 4, 166
tertiary prevention 9
see also squamous cell carcinoma
oral carcinogenesis 23, 32–46
oral cavity, anatomy 14–16, 17
oral epithelial disease, definition 11
oral examination 76
oral health 4, 39, 43
risk of oral cancer 45
oral mucosa 14–30
abnormalities 4, 5
alveolar 16, 21
function 17
lamina propria 18–19
lining 19–21
masticatory 21
microanatomy 17–19
oral submucous fibrosis 66
oral precancer, definition 10
oral precancerous premalignant conditions 50
definition 10
oral precancerous premalignant lesions 50
definition 10
oral precursor lesion, definition 11
oral submucous fibrosis 66–7
malignant transformation 67
oropharynx 15, 16
squamous cell carcinoma 17
orthokeratinisation 18

p53 177–8, 179
palatine tonsils 16
palatoglossal folds 14
pan-oral disease, diagnostic problem 82
pathology 94–105
biopsy techniques 94–6
dysplasia grading 99–100, 101, 102–3, 104
grading systems 96
histopathological features 97–9
limitations in conventional techniques 104
role of pathologist 96–7
service organisation 98–9
patient care pathways 210–11
patient experiential studies 183
Patterson–Kelly–Brown syndrome 68
peroxisome proliferator activator receptor inhibitors (PPARIs) 179
persistent disease, definition 11, 143, 144
photodynamic therapy 112
Plummer–Vinson syndrome 68
potentially malignant disorders 50–1
definition 10
precancer state 2
clinical behaviour prediction 5, 6
epidemiology 6–7
management 6
treatment strategies 6

prevention of oral precancer 172–4
malignant transformation 209
primary 172
strategies 211
see also oral cancer, prevention
prognosis 211
malignant transformation 168
prognostic research 183
progression model for oral carcinogenesis 4, 36–8
proliferative verrucous leukoplakia (PVL) 56–8
biopsy 102
case history 192–4
classification 98, 99
diagnosis 58, 192, 193
histopathology 100, 102
invasive carcinoma 102
laser surgery 193
malignant transformation 58
proteomic research 180–1
public awareness 77, 109
campaigns 173
public health promotion schemes 174
squamous cell carcinoma 7
strategies 211
radiotherapy, adjuvant 9, 134
randomised controlled trials (RCTs) 182
recurrent disease
definition 11, 144
new-site 145
prevention 9
same-site 144
rete processes 20, 21
retromolar trigone 16
risk factors
modification 109–11
oral cancer 2, 3–4
oral carcinogenesis 38–40, 41, 42–4
profiling 44–5
reinforcement of behaviours 134–5
see also alcohol exposure; tobacco exposure
risk stratification 109
salivary glands 15
ducts 21
sublingual 15
see also submandibular salivary gland
same-site recurrence 144
screening 76–7
sebaceous glands, buccal tissue 21
sialadenitis, chronic obstructive 132, 133
sideropenic dysphagia 68
single lesion disease, definition 11
smoking cessation
  multiple lesion disease 190–1
  prevention of oral precancer 172
  risk factor modification 109–10
socioeconomic status 4, 43
  risk of oral cancer 45
soft palate 15, 16
  clinical examination 78
  junction with hard palate 14
  laser surgery 127–8
squamous cell carcinoma 17
squamous cell carcinoma 2, 3, 33, 34
  active surveillance 165
  anatomical site predilection 29
  clinical signs 165–6
  de novo 167
  definition 11
  development 11
    in leukoplakia 157, 159–60
  epithelial cell instability 2
  floor of mouth 14, 166
  genetic disorder 36
  histological appearance 32
  immunocompromised patients 63
  immunosuppressed patient 198–9
  infiltrative 166
  laser surgery 199, 204
  late-presenting 166
  leukoplakia malignant
    transformation 62, 157
    metastases 166, 189
    multiple lesion disease 73
    oral submucous fibrosis 67
  oropharynx 17
  precursor lesions 167
  preinvasive phase 97
  public health issue 7
  risk of progression to 158–61
  soft palate 17
  survival rate 166
  treatment 9
  tumour spread 2, 3
  ulcerated 166
  unexpected 167–8, 187–9
squamous epithelium
  basal cell layer 17–18
  keratinised layer 17, 18
  layers 17–19
  malignant transformation 3
  masticatory mucosa 21
  microanatomy 17–19
oral mucosa 19, 20
  prickle cell layer 17, 18
  squamous intra-epithelial neoplasia (SIN) 97, 98
  system 102–3, 104
stem cells 17–18
  keratinocyte 25–6
Stenson’s duct 21
sublingual region 15
  multiple ducts of Rivinus 21
  sublingual salivary gland 15
  submandibular salivary gland 15, 21
  duct 16, 21
  leukoplakia overlying 166, 175
  obstruction after laser surgery 132, 133
  swelling after laser surgery 132, 133
surgical excision 108
surgical techniques 113–23, 124–5, 126–33
oral cancer 208
see also laser surgery
swallowing difficulties, post-laser surgery 133
syphilis 70–1
taste buds 18
telomere shortening 180
terminology 9–11, 49–51
tissue fluorescence spectroscopy 87–8
tissue reflectance 85–6
tobacco exposure 3
  aetiology of oral cancer 38, 39–40, 41
  alcohol synergistic effects 110
  chronic hyperplastic candidosis 69, 70
  erythroplakia 59
  further disease risk 145, 150
  hyperkeratosis 201–3
  incidence of oral cancer 7
  leukoplakia 52–3
  malignant transformation risk 165
  multiple lesion disease 71, 72
prevention
  oral cancer 9
  oral precancer 172–3
  recurrent disease risk 145, 150
  risk modification 109–10
  risk of oral cancer 38, 39–40, 41, 45
smokeless tobacco 110
soluble carcinogens 29
toombak habit 201–3
see also smoking cessation
tongue 15
base 16
clinical examination 78, 79
clinical resolution of lesion 142, 143
dorsum surgery 122, 125
granulation tissue 132
laser surgery 121, 122, 123–4, 125
complications 131–2
lateral surgery 121, 123, 124
leukoplakia 15
malignant transformation 157
lichen planus 64, 65, 66
mucosa 20–1
squamous cell carcinoma 33, 34
leukoplakia malignant transformation 157
tethering after laser surgery 132
ventral surgery 20–1, 123–4, 125
tonsils
clinical examination 78
lingual 23
palatine 16
toombak habit 201–3
transit-amplifying cells 17, 18
translational research 182–3
treatment strategies 9
tumour suppressor genes, inactivation 36
vascular endothelial growth factor (VEGF) 179
VELscope® 86–7, 118
follow-up examination 135
vermillion border, lip 19
viral vectors 177–8
vital tissue staining 84–5
vitamin A therapy 112
vitamin C therapy 112
vitamin E therapy 112
von Ebner’s glands 23
Wharton’s duct 21
World Health Organization (WHO)
classification 98, 99, 103
dysplasia grading 99, 100, 101, 102, 103
xeroderma pigmentosum 43